Merck Serono

What Merck Serono does

Merck Serono is the Healthcare business unit of Merck KGaA, Darmstadt, Germany, operating under the EMD Serono brand in the United States and Canada. The company develops and commercializes prescription medicines, medical devices, and digital health solutions across six therapeutic areas: Rare Tumors (desmoid tumors, neurofibromatosis type 1, tenosynovial giant cell tumor), Oncology (Merkel Cell Carcinoma, head and neck, colorectal, and lung cancers), Neurology and Immunology (multiple sclerosis with over 20 years of experience), Fertility (where it claims global market leadership), Endocrinology (growth hormone deficiency), and General Medicine (diabetes, cardiovascular, thyroid disorders). Core technologies include biomarker-based personalized treatment matching, mRNA platforms, self-injection devices paired with disease monitoring software for MS patients, and patient-directed digital solutions built with patient input for care beyond the clinic.

The business operates on a prescription pharmaceutical model, selling primarily through direct sales relationships with hospitals, clinics, and healthcare providers globally. Distribution is supported by regional subsidiaries (e.g., EMD Serono in the US/Canada) and a dedicated clinical trial supply subsidiary (Merck KGaA Export GmbH), reaching patients across Africa, Asia, Europe, Latin America, North America, and Oceania. Pricing for prescription pharmaceuticals is not publicly disclosed. Merck Serono is one of three business sectors of Merck KGaA, Darmstadt, Germany, alongside Life Science (MilliporeSigma) and Electronics (EMD Electronics); however, revenue figures are not disclosed at the business-unit level in the available data.

Recent activity in 2026 includes the dosing of the first patient in a Phase 3 study of Precem-TcT for metastatic colorectal cancer (May 2026), a collaboration with Versant Ventures to launch Saturnus Bio focused on rare genetic cardiomyopathies (June 2026), and leadership changes including the appointment of Monia Vial as President of EMD Serono and Miguel Fernández Alcalde as Head of Global Commercial Strategy (June 2026).

Name

Merck Serono

Legal name

Merck KGaA, Darmstadt, Germany

Website

https://biopharma.merckgroup.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Merck Serono is Merck KGaA's Healthcare business unit, operating as EMD Serono in North America. It develops prescription medicines, medical devices, and digital health solutions across rare tumors, oncology, multiple sclerosis, fertility, endocrinology, and general medicine, with global fertility market leadership.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK)

Keywords

• Prescription pharmaceuticals
• Fertility treatments
• Oncology medicines
• Multiple sclerosis therapies
• Biopharmaceutical products

Headquarters

HQ city

Darmstadt

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Distribution channels3 records

Marketing channels6 records

Core offering

Merck Serono develops, manufactures, and commercializes prescription medicines and associated medical devices across six therapeutic areas: Rare Tumors (desmoid tumors, NF1, TGCT), Oncology (Merkel Cell Carcinoma, head and neck, colorectal, and lung cancers), Neurology & Immunology (Multiple Sclerosis), Fertility, Endocrinology (growth hormone deficiency), and General Medicine (diabetes, cardiovascular, thyroid). It complements medicines with intelligent self-injection devices and disease monitoring software, particularly for MS, and leverages biomarker matching and mRNA technology to enable personalized treatment.

Product overview

Merck Serono (EMD Serono in North America) operates as the Healthcare business of Merck KGaA, Darmstadt, Germany, offering a portfolio of medicines, medical devices, and digital health solutions across six therapeutic areas: Rare Tumors (desmoid tumors, NF1, TGCT), Oncology (Merkel Cell Carcinoma, head and neck, colorectal, lung cancers), Neurology & Immunology (Multiple Sclerosis with injection devices and monitoring software), Fertility (treatments and IVF technologies), Endocrinology (growth hormone deficiency), and General Medicine (diabetes, cardiovascular, thyroid). The company uses a patient-directed approach, integrating digital solutions built with patient input, and operates as part of a tri-business structure alongside Life Science and Electronics.

Differentiator

Problem solved

Functional benefit

Brands

• Vibrant Thoughts: Blog featuring science and technology perspectives on disease understanding and patient innovation
• The Future Transformation

Products and services

• Rare Tumors medicines

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Astellas Pharma: Japanese biopharma with strong rare-disease and oncology focus, including work in rare tumors. Comparable therapeutic-area mix and emerging oncology pipeline strategy.
• Sanofi: Large biopharma with rare-disease focus via Genzyme, MS franchise (Lemtrada, Aubagio), and fertility exposure via its consumer health division. Comparable breadth across Merck Serono's therapeutic areas.
• Novartis: Global biopharma with overlapping portfolios in neurology/MS, oncology, and women's health/reproductive medicine. Direct competitor in MS and fertility, and active in biomarker-driven oncology.
• Vertex Pharmaceuticals: Specialized biopharma focused on serious diseases including rare genetic disorders. Comparable precision-medicine approach and growing rare-disease franchise relevant to Merck Serono's Saturnus Bio initiative.
• Ipsen: Specialty biopharma with rare-disease and oncology focus, including treatments in neurofibromatosis and other rare tumors. Most direct comparable to Merck Serono's rare-tumors franchise.
• Biogen: Pure-play neurology/neuroscience biopharma with leading MS franchise (Tysabri, Tecfidera). Direct MS competitor with similar focus on neuro-immunology and chronic disease management.
• Roche: Swiss-headquartered biopharma with deep oncology and biomarker-driven diagnostics franchises (Roche Diagnostics/Genentech), directly comparable in personalized oncology strategy and global reach.

Broad incumbents

• Pfizer: Global pharmaceutical incumbent with broad oncology, neurology, and rare-disease portfolios. Overlaps in oncology pipeline and MS competitor presence, with broader scale and commercial reach.
• Bristol-Myers Squibb: Major oncology-focused biopharma with deep immuno-oncology pipeline. Competes with Merck Serono's biomarker-driven oncology strategy across multiple solid tumor indications.
• Bayer: German-headquartered life sciences company with pharmaceutical division spanning women's health, oncology, and cardiovascular. Comparable in therapeutic-area breadth and European commercial footprint.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/merckgroup
• Facebookfacebook.com/emdgroup
• LinkedInlinkedin.com/company/14328
• Instagraminstagram.com/_emdgroup_/?hl=en

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merck Serono